NeoPredics – Investor Relations DE

INVESTOR RELATIONS

Kontaktieren Sie uns jederzeit gerne: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

Vorhersage Plattform um klinische Entscheidungen zu Unterstützen

Warum in NeoPredics investieren?

Software-as-a-Service
Digital Health
bahnbrechende Vorhersagesoftware
weltweites Marktpotenzial
Engagiertes Team von Wissenschafts- und Marktexperten

Investor Kalender

NeoPredics nimmt an folgenden Investorenkonferenzen teil:

INVESTOREN MEDIEN ZENTRUM

Thorsten Waloschek Presents NeoPredics at LSI USA ’23 (Youtube)

Mayo Clinic Platform_Accelerate: NeoPredics (external link to Youtube)

Pressemeldungen

Cairman of the Board

NeoPredics Welcomes Todd Usen as Chairman of the Board

NeoPredics AG Germany and NeoPredics USA Inc., is pleased to announce the appointment of Mr. Todd Usen as Chairman of the Board, marking an exciting new chapter for the company as it continues to grow its impact in maternal and neonatal healthcare.

COVERAGE BY COMPANYGLANCE

Coverage on NeoPredics by companyglance.com

Coverage on NeoPredics by companyglance.com: NeoPredics: Revolutionizing Maternal And Neonatal Care With Predictive Analytics (Published: Sep 16, 2024)

Investment from Springhood Ventures

NeoPredics Secures Investment from Springhood Ventures to Advance Neonatal Health Innovations

Fort Lauderdale, FL - NeoPredics, a leading predictive analytics company focused on neonatal, maternal, and perinatal health, is pleased to announce an investment from Springhood Ventures. This investment will further accelerate the development and deployment of NeoPredics's innovative solutions aimed at improving outcomes for newborns worldwide.

Multi-Center Observational Study

Clinical Decision Support Company NeoPredics AG Completes Prospective Multi-Center Observational Study

Basel, Switzerland, Regensburg, Germany, and Ft. Lauderdale, FL, USA, May 25, 2022 – NeoPredics AG, a privately held maternal and neonatal clinical decision support company focused on the development and commercialization of intelligent algorithms to predict dynamic progression of disease parameters during the first 1,000 days of life, announced at a poster presentation during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine held in Aachen, Germany, that a prospective multi-center observational study was formally completed.

NeoPredics PRESENT AT BIOTECH SHOWCASE™ 2022

Breakthrough Prediction Software Platform of NeoPredics shown at BIOTECH SHOWCASE

Regensburg, Germany. 22nd of December 2021 – NeoPredics today announced that it will be presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation.

Start-up company opens first US office

NeoPredics starts marketing its prediction software platform in USA

November 15, 2021 - With the establishment of NeoPredics USA in Fort Lauderdale (Florida) the German/Swiss NeoPredics AG starts its US business and pushes its internationalization strategy. The start-up company develops prediction software for hospitals and neonatal units based on scientific and clinical data as well as science-based algorithms.

Wer ist NeoPredics?

NeoPredics AG is a Swiss company located in Basel with subsidiaries in Regensburg, Germany and Ft. Lauderdale, Florida, USA.

Kontakt

Sie möchten uns näher kennenlernen?
Schreiben Sie uns gerne Ihre Fragen oder Wünsche!
Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.